doi: 10.3389/fphys.2022.983961 Received 01 July 2022 Accepted 07 September 2022 Published 20 September 2022 Volume 13 - 2022 Edited by Claudio de Lucia, Scientific Clinical Institute Maugeri (ICS Maugeri), Italy Reviewed by Oscar Lorenzo, Health Research Institute Foundacion Jimenez Diaz (IIS-FJD), Spain Raffaele Carraro, La Princesa University Hospital, Spain Updates Copyright 2022 Kreiner, Hovingh and von Scholten
A randomized controlled trial published in the New England Journal of Medicine demonstrated that tesamorelin significantly reduced visceral adipose tissue in patients with abdominal fat accumulation (Falutz et al., 2007)
That said, I do think theres one area of risk that deserves further attention, and thats liquidity
These metabolites modulate pathways of inflammation through the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, toll-like receptor 4 signaling, and macrophage driven effects in adipocytes, among other mechanisms